Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
about
Cancer immunotherapy: the beginning of the end of cancer?Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsModulation of GITR for cancer immunotherapyMolecular mechanisms of T cell co-stimulation and co-inhibitionWhat future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityTumor infiltrating lymphocytes in ovarian cancerImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potencyCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationCD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses4-1BB agonism: adding the accelerator to cancer immunotherapyBlockade of the B7-H1/PD-1 pathway for cancer immunotherapyCombinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinGalectin-9 controls the therapeutic activity of 4-1BB-targeting antibodiesCD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.Antibody Therapies in Cancer.Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.Genome-wide RNAi screen in IFN-γ-treated human macrophages identifies genes mediating resistance to the intracellular pathogen Francisella tularensis.Human genetic evidence for involvement of CD137 in atherosclerosis.New Immunotherapy Strategies in Breast Cancer.Combination immunotherapy: a road map.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Immune microenvironments in solid tumors: new targets for therapy.Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infectionReprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.Immunotherapy targets in pediatric cancer.Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapyTargeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELALoss of intraepidermal nerve fiber density during SIV peripheral neuropathy is mediated by monocyte activation and elevated monocyte chemotactic proteins.Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm
P2860
Q26752277-CB3FACC5-4BD7-409C-BC4F-319596BB08BCQ26798402-59029120-B3C9-4CE9-A43F-BCFD6DAEECB9Q26823789-CB28D3DE-6230-43B3-88A6-442ACB0E6F54Q26853557-37E25FBC-3BB4-48A7-A03F-9B674B225555Q26864888-6AE50399-A483-4C8F-998E-B257A55876E7Q27012886-1106CFC1-E2C6-4199-B45B-A02DA33AEF30Q27012963-5F9806C6-24A1-4633-B1CF-61918C61A4FDQ27021878-20157285-2530-4ED7-B3D5-12243B2182D7Q27027633-E75611B0-02BF-4305-8CD8-C947ADC581A3Q27676800-5E91E674-F461-4FBC-A74C-2A5AA8AFB27CQ28066199-D245ACE1-7334-404B-8545-42D0EC6B9AF8Q28068378-EA44F99E-3108-478D-AEFF-11E9F9FBC69BQ28072933-7440F6F8-9F67-45C5-8632-05EB698A333BQ28079622-F1BA0C9F-D29D-4E2B-89DE-A30A88E4085EQ28394869-FE6D6999-7D88-48A7-AFC5-6E4EA788A62DQ28537820-6C1D42CA-CEDA-4993-BE78-F0D54223BF7BQ28656460-1F8A02CB-7250-4FAC-BDE3-80DF3CCC77D9Q30573747-545E2AB7-2780-404E-BE6B-8112322CFA51Q31104000-C40232B7-B1BC-4E8F-A9BD-F0B24E90C30AQ33426409-90E75740-8E04-4343-BB98-E40B0085B9BBQ34017748-937C1BB0-9FBC-4163-B50B-62FCB3EB5668Q34168376-D107D453-2623-47E6-91AE-897AF1CFA2D4Q34416210-624C27B6-41DD-4C9B-8CA2-338DA25ED639Q34549227-5A5493DC-5ABC-473D-87B8-776E1FA6BCC9Q34552128-947855BA-F21B-4658-BAD5-7F7439FE6147Q34658452-F23FED26-1F52-4138-825F-568FF5468D48Q34665823-35679112-3872-47BC-AEA6-0E71DA8D4E72Q35107009-77AF4ED2-5C83-479D-AE59-AA689B19D573Q35642044-CBE050E9-64E3-418D-9704-E7E486B68B3CQ35679587-4A1C919E-C1DD-4BE2-A0A9-2159B573D8AAQ35799094-AB0A2625-BB61-4F79-AFEC-4AF1AF1E705EQ35922726-66E653F6-5354-426A-B07A-9FAF0ECDFC9DQ35971029-DBA7BDE3-8BDB-4ED4-93E8-1E80A8B8E521Q36220613-E6B5C87B-CB2A-4CA5-80BB-4BC2522D3BA2Q36349514-8B4B560C-0EE9-4376-BCAD-55AC42922C5AQ36366982-24EDB52B-BF0C-4D44-BF07-36F7F1082BAEQ36383524-0EB070BE-A627-4F32-BCD5-1B186154DFEDQ36456487-EABA910A-7BA1-4A36-A6E7-7A64714EC06AQ36567448-4420F2F9-D00E-43E9-830A-C24A5D6FD96BQ36621100-E3B3B853-BB4D-425D-A012-520640F0A235
P2860
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@en
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@nl
type
label
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@en
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@nl
prefLabel
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@en
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@nl
P2093
P1433
P1476
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
@en
P2093
Ester Simeone
Ignacio Melero
Yang-Xin Fu
P304
P356
10.1053/J.SEMINONCOL.2010.09.008
P407
P577
2010-10-01T00:00:00Z